I-XW-053
Based on 1 Customer Validation
I-XW-053 is a specific anti-HIV-1 capsid inhibitor (IC50=164.2 μM). By binding to the CA NTD-NTD hexamerization interface and the R173 region of CTD (Kd=66.3 μM), I-XW-053 disrupts capsid function and reduces polymerization levels. I-XW-053 effectively blocks HIV-1 uncoating, inhibits reverse transcription and early replication, and exhibits broad-spectrum activity against primary HIV-1 isolates in peripheral blood mononuclear cells. I-XW-053 can be widely used in studies related to HIV-1 infection.
For research use only. We do not sell to patients.
- Purity: 99.71%
- CAS No.: 5496-35-5
- Formula: C22H16N2O2
- Molecular Weight:340.38
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Highly Selective Inhibitors Library
HY-L158
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
MCE Kinase Hinge Binder Fragment Library
HY-L907
-
Anti-Infection Compound Library
HY-L002
-
Antiviral Compound Library
HY-L027
Biological Activity
|
HIV-1 |
I-XW-053 (0.86-110 μM; 30 min+48 h) inhibits single-round HIV-1 (YU-2 envelope) infection of Cf2Th/CD4-CCR5 cells, with an IC50 of 22.5 μM[1].
I-XW-053 potently inhibits the replication of multiple primary HIV-1 isolates in human primary PBMC, with no cytotoxicity detected[1].
I-XW-053 (100 μM; 24 h) significantly reduces the levels of HIV-1 late reverse transcription products in P4-R5 MAGI cells, U87.CD4.CXCR4 cells, and MDM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:P4-R5 MAGI cells, U87.CD4.CXCR4 cells, monocyte-derived macrophages (MDMs)
-
Concentration:100 μM
-
Incubation Time:24 h
-
Result:Reduced the amount of detectable HIV-1 late RT products by an order of magnitude or greater in all three tested cell types.
Chemical Information
-
CAS No. 5496-35-5
-
Appearance Solid
-
Molecular Weight 340.38
-
Formula C22H16N2O2
-
Color Off-white to light yellow
-
SMILES
O=C(O)C1=CC=C(C2=NC(C3=CC=CC=C3)=C(C4=CC=CC=C4)N2)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (293.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kortagere S, et al. Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid. J Virol. 2012;86(16):8472-8481. [Content Brief]
[2]. Chia T, et al. A Small Molecule, ACAi-028, with Anti-HIV-1 Activity Targets a Novel Hydrophobic Pocket on HIV-1 Capsid. Antimicrob Agents Chemother. 2021;65(10):e0103921. [Content Brief]
[3]. Fricke T, et al. Human cytosolic extracts stabilize the HIV-1 core. J Virol. 2013;87(19):10587-10597. [Content Brief]
[4]. Kortagere S, et al. Structure-activity relationships of a novel capsid targeted inhibitor of HIV-1 replication. J Chem Inf Model. 2014;54(11):3080-3090. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9379 mL | 14.6895 mL | 29.3789 mL | 73.4473 mL |
| 5 mM | 0.5876 mL | 2.9379 mL | 5.8758 mL | 14.6895 mL | |
| 10 mM | 0.2938 mL | 1.4689 mL | 2.9379 mL | 7.3447 mL | |
| 15 mM | 0.1959 mL | 0.9793 mL | 1.9586 mL | 4.8965 mL | |
| 20 mM | 0.1469 mL | 0.7345 mL | 1.4689 mL | 3.6724 mL | |
| 25 mM | 0.1175 mL | 0.5876 mL | 1.1752 mL | 2.9379 mL | |
| 30 mM | 0.0979 mL | 0.4896 mL | 0.9793 mL | 2.4482 mL | |
| 40 mM | 0.0734 mL | 0.3672 mL | 0.7345 mL | 1.8362 mL | |
| 50 mM | 0.0588 mL | 0.2938 mL | 0.5876 mL | 1.4689 mL | |
| 60 mM | 0.0490 mL | 0.2448 mL | 0.4896 mL | 1.2241 mL | |
| 80 mM | 0.0367 mL | 0.1836 mL | 0.3672 mL | 0.9181 mL | |
| 100 mM | 0.0294 mL | 0.1469 mL | 0.2938 mL | 0.7345 mL |
I-XW-053 Related Classifications
HY-103078 Related Classifications
Powered by Bioz
- I-XW-053
- 5496-35-5
- HIV
- Reverse Transcriptase
- peripheral blood mononuclear cells
- HIV-1 capsid (CA) N-terminal domain (NTD)
- HIV-1 CA-NC complex
- primary HIV-1 isolates
- U87.CD4.CXCR4 cells
- simian immunodeficiency virus (SIV)
- MDMs
- Cf2Th/CD4-CCR5 cells
- P4-R5 MAGI cells
- HIV-1 capsid (CA) C-terminal domain (CTD)
- Inhibitor
- inhibitor
- inhibit